# Science Advances

### Supplementary Materials for

#### cSTAR analysis identifies endothelial cell cycle as a key regulator of flowdependent artery remodeling

Hanqiang Deng et al.

Corresponding author: Boris N. Kholodenko, boris.kholodenko@ucd.ie; Martin A. Schwartz, martin.schwartz@yale.edu

*Sci. Adv.* **11**, eado9970 (2025) DOI: 10.1126/sciadv.ado9970

#### The PDF file includes:

Figs. S1 to S5 Legends for tables S1 to S5

#### Other Supplementary Material for this manuscript includes the following:

Tables S1 to S5

#### **Supplementary Figure Legends**


**Figure S1. Leukocytes recruitment under LSS and OSS in vivo**. (**A**) Heatmap of log2 fold changes in expression of chemokines that preferentially attract macrophages (CCL2) vs neutrophils (CXCL2 and CXCL8) in PSS, LSS and OSS conditions. (**B**) Left common carotid artery (LCA) ligation to generate low shear stress (LSS): external carotid artery (ECA) and superior thyroid artery (STA) were ligated, leaving internal carotid artery (ICA) and occipital artery (OA) open. (**C**) Left common carotid artery (LCA) ligation to generate oscillatory shear stress (OSS): ECA, STA, ICA and OA were ligated. (**D** and **E**) Representative images (D) and quantification (E) of anti-Myeloperoxidase (MPO, neutrophil marker) on RCA and LCA sections from LSS and OSS models. (**F** and **G**) Representative images (F) and quantification (G) of F4/80 (macrophage marker) on RCA and LCA sections from LSS and OSS models, n=6 mice per group. Scale bars, 25 µm. L, lumen. Data are presented as mean ± s.e.m. \*\*\**P* < 0.001, ns: not significant, calculated by two-way ANOVA with Tukey's multiple comparison.


**Figure S2. CDK2 depletion induces early G1 arrest under OSS**. FUCCI HUVECs were transfected with control (siCtrl) or CDK2 (siCDK2) siRNA for 3 days, and then were subjected to OSS or Static for 24 hours. (**A**) Cells were fixed and mounted with DAPI (4',6-diamidino-2-phenylindole). Representative images are showed. Scale bars, 100  $\mu$ m. (**B**) Quantification of cell cycle state, n=5 experiments, data are presented as mean ± s.e.m. \*\*\**P* < 0.001, ns: not significant, calculated by two-way ANOVA with Tukey's multiple comparison.

**Figure S3. Lung histology images**. (**A**) H&E (Hematoxylin & Eosin) staining of Ctrl and CDK2 iECKO lung sections. V, vessels. Arrowheads are narrowed and occlusive vessels.


Figure S4. Activation of Smad2/3 in CDK2 ECKO lung tissue. (A and B) Representative images and quantification of p-Smad2 Ser465/467 (A) and p-Smad3 Ser423/425 (B) in lung sections from Ctrl and CDK2 iECKO mice, n=6 mice per group. Scale bars, 25  $\mu$ m. Data are presented as mean ± s.e.m. \*\*\**P* < 0.001, calculated by two-tailed unpaired t tests. (C) cSTAR-predicted global responses of the TGF $\beta$ R pathway activity to perturbations of all other core network modules, except TGF $\beta$ R itself. A negative global response of TGF $\beta$ R to CDK2 implies that CDK2 inhibition will activate the TGF $\beta$ R pathway.

**Figure S5. Body weight and plasma lipid analysis**. (**A** and **B**) Body weight, plasma total cholesterol, and triglyceride levels between male (A) and female (B) Ctrl and CDK2 iECKO mice. N=6 mice per group per gender, data are presented as mean ± s.e.m. ns: not significant, calculated by two-tailed unpaired t tests.







В





S-G2-M

















#### **Supplementary Tables**

All supplementary tables are separate Excel files. Below are the table captions.

**Table S1.** The STV vectors determining phenotypic cell state transitions in originaldataspace.

**Table S2.** The STV vectors determining phenotypic cell state transitions in L1000dataspace.

**Table S3.** The cSTAR-inferred local response matrix r: mean values and standarddeviations of the BMRA reconstructed local response matrix elements.

**Table S4.** The global response matrix: cSTAR predicted global response matrix  $-r^{-1}$ .

Table S5. List of secondary antibodies.